Future Pharmaceutical industries
- Company typePrivate
- Founded2011
- HeadquartersCairo, Egypt
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Future Pharmaceutical industries firmographics
Firmographics- Name
- Future Pharmaceutical industries
- Legal name
- Future Pharmaceutical Industries
- Website
- https://fpi-futurepharma.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Ownership category
- akta.pro rank
Future Pharmaceutical industries industry classification
Industry- Product category
- Generic Pharmaceuticals Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
Keywords
Where Future Pharmaceutical industries is headquartered
LocationHeadquarters
- HQ city
- Cairo
- HQ country
- Egypt
- HQ region
- Africa
Offices2 records
Markets served
Future Pharmaceutical industries business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Generic Pharmaceutical Manufacturing: Production and sale of generic medicines across multiple therapeutic categories including cardiovascular, anti-diabetic, CNS, pain management, antibiotics, respiratory, anti-rheumatic, and dermatology products. Revenue generated through wholesale distribution to pharmacies, hospitals, and healthcare providers.
- Contract Manufacturing Services (CMO): Certified contract manufacturing services for multinational pharmaceutical companies (Sanofi, Sandoz, Novartis, Abbott) requiring production under cGMP standards. FPI manufactures products on behalf of these companies in exchange for manufacturing fees or product supply agreements.
- OTC and Dietary Supplements: Over-the-counter pharmaceutical products and dietary supplements sold directly to consumers through pharmacies and retail outlets. Includes products like FPi-Zinc, Broncoxil-N Syrup, Futacare Tab, and Formicee supplements.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Future Pharmaceutical industries product offering
Product offeringCore offering
Future Pharmaceutical Industries (FPI) is a cGMP-certified Egyptian pharmaceutical manufacturer that develops, manufactures, and distributes generic pharmaceutical products across multiple therapeutic categories (cardiovascular, anti-diabetic, GIT, CNS, antibiotics, respiratory, dermatology, and pain management) in diverse dosage forms including tablets, capsules, sachets, powders, liquids, semi-solids, creams, gels, and ointments. The company also produces OTC products and dietary supplements, and provides contract manufacturing services for multinational pharmaceutical companies including Sanofi, Sandoz, Novartis, and Abbott.
Product overview
Future Pharmaceutical Industries (FPI) is a cGMP certified Egyptian pharmaceutical manufacturer producing a diversified portfolio of generic medicines across multiple therapeutic categories. The company manufactures pharmaceutical forms including tablets, capsules, sachets, powder in bottles, liquid oral, topical, semi-solid, cream, gel, and ointments. The product portfolio covers eight therapeutic areas: Orthopedic/Bone and Pain (NSAIDs like Ibuprofen and Etoricoxib), Infection (antibiotics including Cefadroxil, Moxifloxacin, Nitazoxanide), Cardio/Metabolic (antihypertensives including Candesartan and Irbesartan, statins like Rosuvastatin, antidiabetics including Metformin combinations), ENT (antihistamines like Ebastine, vestibular agents like Betahistine), Gastroenterology (PPIs including Esomeprazole, Lansoprazole, Pantoprazole), Neuro/Psychiatry (antiepileptics including Levetiracetam, Brivaracetam, antidepressants including Escitalopram, Fluoxetine, Mirtazapine, antipsychotics including Quetiapine), Sexual Dysfunction (Tadalafil), and OTC/Dietary Supplements (vitamins, zinc supplements). FPI also offers contract manufacturing services for multinational pharmaceutical companies.
Differentiator
Problem solved
Functional benefit
Products and services
- Contract Manufacturing Services (CMO)
Quantifiable outcome
- Secured multinational pharmaceutical manufacturing partnerships with Sanofi, Sandoz, Novartis, and Abbott through GMP certification compliance
- +1 more outcomes
Companies that use Future Pharmaceutical industries
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Future Pharmaceutical industries technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Future Pharmaceutical industries partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- AbbottcoreAbbott conducted GMP audit on FPI in 2017 and certified the facility. FPI serves as a manufacturing partner for Abbott's pharmaceutical products.
- NovartiscoreNovartis conducted OTC and Pharma GMP audit in March 2014 and certified FPI's manufacturing capabilities. FPI produces Novartis products as a contract manufacturing partner.
- SandozcoreSandoz certified FPI in December 2013 for pharmaceutical industries with highly complex and novel technologies. FPI provides contract manufacturing services for Sandoz products.
- EMEA (European Medicines Agency)minorFPI received EMEA certificate in November 2013, enabling their medical products to be considered for marketing approval in countries outside the EU that reference EMEA assessments.
- SanoficoreSanofi issued FPI a GMP certificate in October 2013 recognizing outstanding quality manual and good manufacturing practices. FPI serves as a contract manufacturing partner for Sanofi, producing pharmaceutical products under their brand at FPI's cGMP-certified facility.
- Sabbour ConstructionminorSabbour Construction designed FPI's manufacturing facility, which spans over 16,400 m2 in Badr City Industrial Zone, Cairo, Egypt.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Future Pharmaceutical industries competitors and assessment
Company assessmentBroad incumbents
- Cipla: Cipla is one of the world's largest generic pharmaceutical manufacturers with active presence across Africa and the Middle East. Comparable to FPI on molecule breadth, export-driven growth model, and CMO/partnering strategy with multinationals.
- Aurobindo Pharma: Aurobindo is a large Indian-headquartered generics manufacturer with global reach and significant CMO/formulations services. Comparable to FPI on manufacturing scale, generic breadth, and outward market strategy — though at materially larger scale.
- Hikma Pharmaceuticals: Hikma is a large MENA-headquartered generic and injectable pharmaceutical manufacturer with significantly broader scale and product range than FPI. Comparable on geography, generic-and-injectable strategy, and contract manufacturing capabilities.
Direct peers
- EVA Pharma: EVA Pharma is one of Egypt's largest domestic pharmaceutical manufacturers with a similarly diversified generic portfolio and multi-country MENA/Africa export footprint. Direct overlap on therapeutic breadth, cGMP-grade manufacturing, and CMO-style partnerships.
- EIPICO (Egyptian International Pharmaceutical Industries Company): EIPICO is a major Egyptian generic pharmaceutical manufacturer producing tablets, capsules, injectables, and sterile products. Comparable to FPI on geography, dosage-form breadth, and target customers (Egyptian pharmacies, hospitals, and regional export).
- Egyptian Company for Cosmetics & Pharmaceuticals (ECCPA / CID): CID is an Egyptian pharmaceutical manufacturer producing generics across multiple therapeutic categories including CNS, cardiovascular, anti-infectives, and respiratory. Direct overlap with FPI on domestic-market portfolio, dosage forms, and Egyptian regulatory positioning.
- Pharco Pharmaceuticals: Pharco is one of the largest Egyptian pharmaceutical groups, producing generics and OTC products with strong regional exports. Directly comparable to FPI on therapeutic breadth, regional distribution, and Egyptian-market positioning.
- Memphis Pharmaceuticals: Memphis is an Egyptian pharmaceutical company producing generics and OTC products with regional distribution. Comparable to FPI on Egypt-centric operations, generic-OTC portfolio mix, and similar therapeutic-category coverage.
Regional players
- Julphar (Gulf Pharmaceutical Industries): Julphar is a UAE-based generic pharmaceutical manufacturer producing across multiple dosage forms and exporting across MENA. Comparable to FPI on portfolio breadth, regional distribution, and contract manufacturing ambitions.
- SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): SPIMACO is a Saudi-based pharmaceutical manufacturer producing generics and serving MENA markets. Comparable to FPI on regional positioning, generic focus, and contract manufacturing for multinational partners.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Future Pharmaceutical industries social profiles
Digital presenceFuture Pharmaceutical industries compliance and trust
Trust signalCompliance7 records
Future Pharmaceutical industries financial estimates
Financial estimateRevenue estimate
Valuation estimate
Future Pharmaceutical industries leadership team
Management profileNumber of profiles
Profiles1 record
Future Pharmaceutical industries funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Future Pharmaceutical industries M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Future Pharmaceutical industries
What does Future Pharmaceutical industries do?
Future Pharmaceutical Industries (FPI) is a cGMP-certified Egyptian pharmaceutical manufacturer that develops, manufactures, and distributes generic pharmaceutical products across multiple therapeutic categories (cardiovascular, anti-diabetic, GIT, CNS, antibiotics, respiratory, dermatology, and pain management) in diverse dosage forms including tablets, capsules, sachets, powders, liquids, semi-solids, creams, gels, and ointments. The company also produces OTC products and dietary supplements, and provides contract manufacturing services for multinational pharmaceutical companies including Sanofi, Sandoz, Novartis, and Abbott.
Is Future Pharmaceutical industries a public or private company?
Future Pharmaceutical industries is a private company. It is classified as private equity controlled and is currently operating.
When was Future Pharmaceutical industries founded?
Future Pharmaceutical industries was founded in 2011. It employs 501 to 1,000 people.
Where is Future Pharmaceutical industries based?
Future Pharmaceutical industries is headquartered in Cairo, Egypt, in the Africa region.
How does Future Pharmaceutical industries make money?
Three revenue lines are on record. Generic Pharmaceutical Manufacturing is the primary driver. The others are contract Manufacturing Services (CMO) and OTC and Dietary Supplements.
Who are Future Pharmaceutical industries's main competitors?
Broad incumbents on record are Cipla, Aurobindo Pharma and Hikma Pharmaceuticals. Direct peers are EVA Pharma, EIPICO (Egyptian International Pharmaceutical Industries Company), Egyptian Company for Cosmetics & Pharmaceuticals (ECCPA / CID), Pharco Pharmaceuticals and Memphis Pharmaceuticals. Regional players are Julphar (Gulf Pharmaceutical Industries) and SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation).
Does Future Pharmaceutical industries have an API?
No public API is recorded for Future Pharmaceutical industries.
What industry is Future Pharmaceutical industries in?
Future Pharmaceutical industries's product category is Generic Pharmaceuticals Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.